ArticleFrontiers in microbiology2019
Sequence Types, Clonotypes, Serotypes, and Virotypes of Extended-Spectrum β-Lactamase-Producing
Article in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 52 citations in OpenAlex.
- Genomic characterization of extended-spectrum β-Lactamases (ESBLs)-producing Escherichia coli recovered from bloodstream infections in China.BMC microbiology · 2026Article
- Global survey of extraintestinal pathogenic Escherichia coli identifies stable serogroup-virulence-resistance linkages.Genome medicine · 2026Article
- Evaluation of Virulence Profiles and Molecular Typing of ESBL-Producing UropathogenicInfection and drug resistance · 2026Article
- Whole-genome characterisation of high-risk ST131 and the emerging ST1193 UPEC lineages in Romanian patients with recurrent urinary tract infections.Frontiers in microbiology · 2026Article
- Infective endocarditis caused byThe Journal of international medical research · 2025Article
- Escherichia coli causing bloodstream infections in Mexican paediatric patients: molecular typing, antimicrobial resistance, virulence factors, and clinical features.BMC infectious diseases · 2025Article
- Molecular characterization of extended-spectrum β-lactamase-producing Escherichia coli isolated from lower respiratory tract samples between 2002 and 2019 in the Central Slovenia region.Annals of clinical microbiology and antimicrobials · 2024Article
- Fungus-mediated synthesis of Se-BiO-CuO multimetallic nanoparticles as a potential alternative antimicrobial against ESBL-producingFrontiers in cellular and infection microbiology · 2024Article
- Fluoroquinolone resistance in complicated urinary tract infections: association with the increased occurrence and diversity ofFrontiers in cellular and infection microbiology · 2024Article
- First Report and Characterization of theMicroorganisms · 2023Article
- Decolonizing drug-resistantMicrobiology (Reading, England) · 2023Article
- Possible step-up in prevalence for Escherichia coli ST131 from fecal to clinical isolates: inferred virulence potential comparative studies within phylogenetic group B2.Journal of biomedical science · 2022Article
- Occurrence and Genomic Characterization of Clone ST1193 Clonotype 14-64 in Uncomplicated Urinary Tract Infections Caused by Escherichia coli in Spain.Microbiology spectrum · 2022Article
- Whole-genome-sequence-based characterization of an NDM-5-producing uropathogenic Escherichia coli EC1390.BMC microbiology · 2022Article
- Comparative genomic analysis of ESBL-producingJAC-antimicrobial resistance · 2022Article
- Antimicrobial Resistance inAntibiotics (Basel, Switzerland) · 2022Article
- A role for ColV plasmids in the evolution of pathogenic Escherichia coli ST58.Nature communications · 2022Article
- Molecular Epidemiology and Presence of Hybrid PathogenicMicroorganisms · 2022Article
- Secreted Autotransporter Toxin (Sat) Mediates Innate Immune System Evasion.Frontiers in immunology · 2022Article
- Ten Years of Population-Level Genomic Escherichia coli and Klebsiella pneumoniae Serotype Surveillance Informs Vaccine Development for Invasive Infections.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to examine the prevalence and determine the molecular characteristics of extended-spectrum β-lactamase-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.